Previous 10 | Next 10 |
WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effectiv...
Biopharmaceutical company Adagio Therapeutics ( NASDAQ: ADGI ) changed its name to Invivyd. The company will begin trading under the new ticker symbol IVVD on the Nasdaq Global Market from Sep. 13. The new name considers the company's strategy associated with the d...
Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron sublineages BA.1, BA.2, BA.4, BA.5 and BA.2.75, as well as SARS-CoV-1 Antibodies target...
New name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunity The Invivyd corporate mission is to provide antibody solutions that provide superior protection against viral d...
Adagio Therapeutics press release ( NASDAQ: ADGI ): Q2 GAAP EPS of -$0.47. Cash and cash equivalents were $475 million as of June 30, 2022. For further details see: Adagio Therapeutics GAAP EPS of -$0.47
$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and Treatment with Plans to Enter Clinical Trials in the First Quarter of 2023 WALTHAM...
Gainers: Burning Rock Biotech ( BNR ) +4% . TripAdvisor ( TRIP ) +2% . comScore ( SCOR ) +2% . Arrowhead Pharmaceuticals ( ARWR ) +2% . Bolt Biotherapeutics ( BOLT ) +2% . Losers: Swvl Holdings ( SWVL ) ...
Adagio Shareholders Overwhelmingly Elected Mithril’s Three High-Quality Director Candidates To the Adagio Board Board Transformation will Advance Company’s Mission to Prevent and Treat COVID19 and Other Infectious Diseases Mithril Capital Mana...
Adagio Therapeutics ( NASDAQ: ADGI ) has named interim chief executive officer and chief operating officer David Hering, as company’s permanent CEO and a director on the board. “As COVID-19 continues to infect millions worldwide, we are committed to the ongoi...
WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, announced today that industry and infectiou...
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in ...
Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses Invivyd’s new data is...
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Heal...